Download App

Log in to access Online Inquiry
Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

INDP Indaptus Therapeutics

2.640-0.110-4.00%
Close 05/23 20:00 ET
2.390-0.25-9.47%
Pre Mkt Price 05/24 08:10 ET
High
2.740
Open
2.530
Turnover
563.05K
Low
2.500
Pre Close
2.750
Volume
211.54K
Market Cap
21.80M
P/E(TTM)
Loss
52wk High
28.830
Shares
8.26M
P/E(Static)
Loss
52wk Low
2.130
Float Cap
13.16M
Bid/Ask %
-33.33%
Historical High
24760.000
Shs Float
4.98M
Volume Ratio
0.04
Historical Low
2.130
Dividend TTM
--
Div Yield TTM
--
P/B
0.65
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.25%
Amplitude
8.73%
Avg Price
2.661
Lot Size
1
Float Cap
13.16M
Bid/Ask %
-33.33%
Historical High
24760.000
Shs Float
4.98M
Volume Ratio
0.04
Historical Low
2.130
Dividend TTM
--
P/B
0.65
Dividend LFY
--
Turnover Ratio
4.25%
Amplitude
8.73%
Avg Price
2.661
Lot Size
1
Price Forecast

No Data

News

Comment